跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,456 条关于
“Yuhan Corp.”
全部
6,456
临床试验
4,944
药物
536
机构
386
资讯
590
去年
Yuhan Corp. Sees 690% Surge in Q3 Operating Profit Driven by Lazertinib Milestone Payment
去年
Yuhan Corp Sees Profit Surge After FDA Approval of Lung Cancer Drug Leclaza
2年前
FDA Approves Lazertinib Plus Amivantamab for First-Line EGFR-Mutated NSCLC
2年前
Leclaza Monotherapy Shows Promise in EGFR-Mutated NSCLC
2个月前
Yuhan Corporation Presents Phase 1b Results for Novel Anti-IgE Allergy Drug Lesigercept at EAACI 2026
去年
Yuhan Corporation Receives $15 Million Milestone from Janssen Following Japan Launch of Lazertinib-Amivantamab Combination for EGFR-Mutated NSCLC
去年
Yuhan's Lung Cancer Drug Leclaza Secures European Approval in Combination Therapy
去年
EMA Panel Recommends Lazertinib and Amivantamab Combination for First-Line EGFR-Mutated NSCLC
去年
Immuneoncia Therapeutics Raises $24M in Successful Kosdaq IPO for Cancer Drug Development
去年
Yuhan's Leclaza Secures FDA Approval for NSCLC Treatment, Marking Historic Entry into US Market
第 1 页,共 59 页
上一页
下一页